Frederick W. Holtsberg

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.

F. Izzo, P. Vallone, S. Curley, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Cancer Research.

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

S. Curley, V. Prieto, J. Bomalaski, 2004, Cancer.

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Journal of controlled release : official journal of the Controlled Release Society.

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Medical science monitor : international medical journal of experimental and clinical research.

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin

J. B. Thomas, J. Bomalaski, M. A. Clark, 2002 .

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

F. Izzo, P. Ascierto, E. Simeone, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regression of hepatocellular cancer in a patient treated with arginine deiminase.

S. Curley, J. Bomalaski, M. A. Clark, 2003, Hepato-gastroenterology.

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Cancer research.

Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, The Journal of rheumatology.

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.

J. B. Thomas, J. Bomalaski, M. A. Clark, 2002, The Biochemical journal.